John McCann, MD
Ophthalmology · Columbia, MONPI 1326006917
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,060 of the $8,351 with a category attached, or 84.5%. Amgen accounts for 98.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $8,048 and has fallen 99.3% since, to $57 in 2025.
Across 22 payments — averaging $379.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8K
- Merz North America, Inc.$92
- Galderma Laboratories, L.p.$22
- Carl Zeiss Meditec AG$19
- Merz Pharmaceuticals, LLC$15
What the payments were for
- Consulting fees$451%
- Speaking & faculty fees$7,06085%
- Travel & lodging$7109%
- Food & beverage$5006%
- Education$160%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $8,203 |
| Merz North America, Inc. | 3 | $92 |
| Galderma Laboratories, L.p. | 2 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$7,184
How this compares
$8,351 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 54 | $595 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $379 |
| Celecoxib | 20 | $244 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Columbia
- Jella AnColumbia$166K
- Mai PhamColumbia$17K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Shachar TauberSpringfield$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.